DBV Technologies (NASDAQ:DBVT) Shares Pass Below Fifty Day Moving Average – Should You Sell?

DBV Technologies S.A. (NASDAQ:DBVT) passed below its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of $3.37 and traded as low as $2.99. DBV Technologies shares last traded at $3.09, with a volume of 24,330 shares trading hands.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on DBVT shares. JMP Securities reiterated a “market outperform” rating and set a $10.00 target price on shares of DBV Technologies in a research note on Tuesday, December 10th. HC Wainwright increased their price objective on DBV Technologies from $25.00 to $35.00 and gave the stock a “buy” rating in a research report on Thursday, October 24th. Finally, StockNews.com assumed coverage on DBV Technologies in a report on Wednesday. They issued a “hold” rating on the stock.

DBV Technologies Trading Down 1.9 %

The business has a 50 day moving average price of $3.37 and a 200-day moving average price of $3.88. The firm has a market capitalization of $63.56 million, a PE ratio of -0.69 and a beta of 0.64.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.